ELOVL2-AS1 suppresses tamoxifen resistance by sponging miR-1233-3p in breast cancer

Tamoxifen (Tam) has long been a top treatment option for breast cancer patients, but the challenge of eliminating cancer recurrence remains. Here, we identify a signalling pathway involving ELOVL2, ELOVL2-AS1, and miR-1233-3p, which contributes to drug resistance in Tam-resistant (TamR) breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyeon Woo, Baek, Minjae, Jung, Sanghyun, Jang, Siyeon, Lee, Hyeonjin, Yang, Seung-Hoon, Kwak, Beom Seok, Kim, Sun Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621244/
https://www.ncbi.nlm.nih.gov/pubmed/37908128
http://dx.doi.org/10.1080/15592294.2023.2276384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621244/
https://www.ncbi.nlm.nih.gov/pubmed/37908128
http://dx.doi.org/10.1080/15592294.2023.2276384

Ejemplares similares